

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



DAWNRAYS PHARMACEUTICAL (HOLDINGS) LIMITED

東瑞製藥(控股)有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2348)

Voluntary Announcement

New Product Pharmaceutical Registration Approval

The board (“Board”) of directors (“Directors”) of Dawnrays Pharmaceutical (Holdings) Ltd. (the “Company”) is pleased to announce that Suzhou Dawnrays Pharmaceutical Co., Ltd., a subsidiary of the Company, has recently received pharmaceutical registration approval (“藥品註冊批件”) from the State Food and Drug Administration (SFDA) for the drug Potassium Citrate Extended-release Tablets (“傑士同®” (Jie Shi Tong)) 1.08g and 0.54g used for the treatment of urinary stones, and the approval numbers are Guo Yao Zhun Zi (“國藥准字”) H20110139 and Guo Yao Zhun Zi (“國藥准字”) H20110140 respectively.

The Board believes that 傑士同® (Jie Shi Tong) will further enhance the group’s product portfolio and bring new business opportunity to the group.

By Order of the Board
Dawnrays Pharmaceutical (Holdings) Ltd.
Li Kei Ling
Chairman

Hong Kong, 20 December, 2011

As at the date of this announcement, the Board comprises eight Directors, of which four are executive directors, namely Ms. Li Kei Ling, Mr. Hung Yung Lai, Mr. Li Tung Ming and Mr. Gao Yi; one is non-executive director, namely Mr. Leung Hong Man; three are independent non-executive directors, namely Mr. Pan Xue Tian, Mr. Choi Tat Ying Jacky and Mr. Lo Tung Sing Tony.

**for identification purpose only*